We're thrilled to announce that we have been recognized in the Clinical Research Team of the Year category at this year's Citeline Awards! We're also humbled to have been shortlisted for Clinical Trial Result of the Year alongside many successful peers in our industry. At our core, we’re guided by a deep respect for science and a passion to change patients’ lives for the better, and we're thankful to have made a notable impact. Congratulations to all nominees and winners! #CitelineAwards
Agios Pharmaceuticals
Pharmaceutical Manufacturing
Cambridge, MA 75,797 followers
Where science meets heart. Passionately committed to transforming the lives of people with genetically defined diseases.
About us
Agios is a biopharmaceutical company that is fueled by connections. We are passionately committed to applying our leadership in the field of cellular metabolism to create life-changing therapies for people living with rare diseases. The bonds we build with patient communities, healthcare professionals, partners and colleagues help elevate our thinking and propel our science to new heights. These connections, combined with our cellular metabolism expertise, have fueled the development and approval of our first-in-class pyruvate kinase (PK) activator, as well as other investigational therapies. We’re a company that cares about our work, each other, and the people who are counting on us the most. We’re inspired to think big and welcome the different perspectives and backgrounds needed to deliver extraordinary results.
- Website
-
http://www.agios.com
External link for Agios Pharmaceuticals
- Industry
- Pharmaceutical Manufacturing
- Company size
- 201-500 employees
- Headquarters
- Cambridge, MA
- Type
- Public Company
- Founded
- 2008
- Specialties
- Biopharmaceuticals, Rare Genetic Diseases, Cellular Metabolism, and Hemolytic Anemias
Locations
-
Primary
88 Sidney Street
Cambridge, MA 02139, US
Employees at Agios Pharmaceuticals
Updates
-
Check out the latest version of our ThalassemiaNEWS newsletter! This issue features excerpts from an interview with Dr. AIi Amid, co-author of ‘Guidelines for the Management of Alpha-Thalassaemia’, recently published by the Thalassaemia International Federation (TIF), and more. Read the full Spring 2024 newsletter below.
-
We are pleased to announce our newest social media channel, "Ally Voices Rising," on Instagram! This account serves as a platform to ultimately raise awareness about hemolytic anemias such as #thalassemia, #sicklecell disease and #PKdeficiency. We're encouraging the genetically defined disease community to forge new bonds by sharing their personal encounters living with these diseases. To explore the diverse world of hemolytic anemias and be part of this supportive network, check out @allyvoicesrising on Instagram here: https://lnkd.in/g66Wj6-f
-
Today, on #ITD2024, we stand in solidarity with the global community of fighters, survivors, and champions battling this rare blood disorder. To mark this significant day, we're honored to share the inspiring stories of Maria and Ann, true warriors living with #thalassemia. These incredible women have bravely navigated the challenges of living with different forms of thalassemia around the globe. We encourage you to learn more about the disease and how you can support the community here: https://lnkd.in/gEDjxcMc
-
During #MentalHealthAwarenessMonth, we're encouraging Agioi to #TakeAMentalHealthMoment and participate in a company-wide Move Challenge. Incorporating regular walking into your routine can have significant benefits for your mental health, including reducing stress, improving mood, enhancing cognitive function, and promoting overall well-being. We're aiming to reach one million steps by the end of May.
This content isn’t available here
Access this content and more in the LinkedIn app
-
We are honored to have supported The Nod to “Naz” Exhibit: A Tribute to Hertz Nazaire traveling art exhibit, presented by Sickle Cell Disease Association of America, Inc. — National, this past week in Boston. After immigrating to the United States from Haiti, Hertz served as an advocate for #sicklecelldisease (SCD) through his art, which reflects his and so many others' challenges with the disease. Learn more about Hertz's story, his advocacy for SCD, and where you can visit the memorial exhibit here: https://lnkd.in/gZUv7XGd
-
Our team will be presenting at the Bank of America Securities 2024 Health Care Conference on Thursday, May 16, at 11:40 a.m. ET. A live webcast can be accessed on our website during the presentation and a replay will be archived for at least two weeks following the presentation. Access the webcast on 5/16 here: https://lnkd.in/epH9SCse View the press release here: https://lnkd.in/emTQ2m6Y
-
We will be presenting at the 2024 RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, at 8:00 a.m. ET. A live webcast can be accessed on our website during the presentation and a replay will be archived for at least two weeks following the presentation. Access the webcast on 5/14 here: https://lnkd.in/epH9SCse Read the full press release here: https://lnkd.in/eWrFDxTn
-
Alejandra Watson is a co-founder and Board President of the PKD Foundation and has worked to extend the reach of the foundation's impact through creating a community through social media. Hear from Alejandra below as she speaks to the importance of connection and hearing others' stories within the #pyruvatekinasedeficiency community. At Agios, we support those living with PKD today and every day.
-
Today, we reported our first quarter 2024 financial results and other business highlights. Tune into the live webcast this morning at 8 a.m. ET or watch the replay on our website in the Events & Presentations section. Read the full announcement below.
Agios Reports Business Highlights and First Quarter 2024 Financial Results – Agios Pharmaceuticals, Inc.
investor.agios.com
Similar pages
Browse jobs
Stock
AGIO
NASDAQ
20 minutes delay
$33.00
0.08 (0.243%)
- Open
- 32.94
- Low
- 32.45
- High
- 33.09
Data from Refinitiv
See more info on